Rxcurve
Medicare Part B payment limits Effective October 1 – December 31, 2026 Posted by CMS September 17, 2026
HCPCS J1746 · per 10 MG

Inj., ibalizumab-uiyk, 10 mg

Products billed under this code include Trogarzo.

Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J1746

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Trogarzo Theratechnologies Inc. 62064-0122-02 40 $3,199.88

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $79.997 +$0.485 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted September 17, 2026
3Q26 $79.512 +$1.837 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted September 15, 2026
2Q26 $77.675 +$0.137 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted September 15, 2026
1Q26 $77.538 −$1.721 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted September 15, 2026
4Q25 $79.259 −$0.127 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted September 8, 2026
3Q25 $79.386 +$2.436 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted March 10, 2026
2Q25 $76.95 −$0.183 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted March 10, 2026
1Q25 $77.133 +$0.069 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted December 19, 2025
4Q24 $77.064 −$0.181 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted June 11, 2025
3Q24 $77.245 +$2.60 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted June 11, 2025
2Q24 $74.645 +$0.021 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted March 11, 2025
1Q24 $74.624 +$0.169 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted December 19, 2024
4Q23 $74.455 +$0.163 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted October 10, 2024
3Q23 $74.292 +$4.681 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted June 5, 2024
2Q23 $69.611 −$0.003 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted February 23, 2024
1Q23 $69.614 −$0.114 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted December 6, 2023
4Q22 $69.728 −$0.031 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted June 22, 2023
3Q22 $69.759 +$3.269 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted June 9, 2023
2Q22 $66.49 +$0.237 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted December 14, 2022
1Q22 $66.253 −$0.141 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted June 8, 2022
4Q21 $66.394 +$2.02 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted June 2, 2022
3Q21 $64.374 +$0.164 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted June 2, 2022
2Q21 $64.21 +$0.16 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted March 1, 2022
1Q21 $64.05 – 10 MG Inj., ibalizumab-uiyk, 10 mg v1, posted December 10, 2021

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files